Abstract
Pneumococcal community-acquired pneumonia (PCAP) and invasive pneumococcal disease (IPD) are important causes of morbidity and mortality in elderly. In the Community-Acquired Pneumonia immunization Trial in Adults (CAPiTA), a randomized double-blind placebo-controlled trial of 84,496 community-dwelling immunocompetent adults over 65 years of age, the 13-valent pneumococcal conjugate vaccine (PCV13) reduced the incidence of first episode of vaccine-type (VT) PCAP with 38 and of VT-IPD with 76% in the modified intention-to-treat population. In The Netherlands, where PCV7 immunization of newborns was introduced in 2007 and replaced by PCV10 in 2011, introduction of PCV13 immunization of elderly--based on 2012 data--would be highly cost effective. However, this is probably different in countries where the VT disease burden has declined more, for instance due to herd effects following child immunization with PCV13. Apart from cost-effectiveness analyses, ethical aspects of PCAP prevention should be taken into account in policy making for pneumococcal vaccination in elderly.
References
Feb 19, 2002·International Journal of Antimicrobial Agents·Helena K Parsons, David H Dockrell
Mar 19, 2002·American Journal of Respiratory and Critical Care Medicine·Vladimir KaplanWalter T Linde-Zwirble
Jan 28, 2004·Archives of Internal Medicine·Jenny T van der SteenGerrit van der Wal
May 17, 2005·Vaccine·Richard Kent Zimmerman
Feb 3, 2007·Vaccine·Froukje Oosterhuis-KafejaPierre Van Damme
Jan 7, 2009·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Anke HussMatthias Egger
Jul 1, 2009·Pediatrics·Susan S HuangJonathan A Finkelstein
Oct 13, 2009·Vaccine·Roman PrymulaLode Schuerman
Aug 24, 2010·Thorax·T WelteD Nathwani
Feb 26, 2011·The European Respiratory Journal·S Ewig, A Torres
May 9, 2012·The Journal of Medicine and Philosophy·Anya Plutynski
Nov 3, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Menno R van den BerghElisabeth A M Sanders
Feb 12, 2013·The European Respiratory Journal·Susanne M HuijtsMarc J M Bonten
Feb 22, 2013·Current Opinion in Infectious Diseases·Marcos I RestrepoAntonio Anzueto
Mar 20, 2013·Geriatrics & Gerontology International·Yohei OshitaniHirotoshi Matsui
Oct 3, 2013·PLoS Medicine·Daniel R FeikinUNKNOWN Serotype Replacement Study Group
Dec 18, 2013·The Pediatric Infectious Disease Journal·Katherine E Fleming-DutraKatherine L O'Brien
Feb 18, 2014·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·A TorresT Welte
Mar 25, 2014·Vaccine·Albert Jan van HoekElizabeth Miller
Aug 12, 2014·The Lancet Global Health·Laura L HammittJ Anthony G Scott
Jan 24, 2015·Vaccine·Gili Regev-YochayUNKNOWN IAIPD group
Feb 7, 2015·The Lancet Infectious Diseases·Matthew R MooreCynthia G Whitney
Mar 19, 2015·The New England Journal of Medicine·Marc J M BontenDiederick E Grobbee
Mar 25, 2015·The Lancet Infectious Diseases·Pauline A WaightElizabeth Miller
Jul 15, 2015·The European Respiratory Journal·Marie-Josée J MangenG Ardine de Wit
Citations
May 14, 2016·Vaccine·Cornelis H van WerkhovenMarc J M Bonten
Sep 30, 2016·Frontiers in Immunology·Ger T Rijkers
Dec 29, 2016·International Journal of Molecular Sciences·Nicola Principi, Susanna Esposito
Jul 20, 2016·International Journal of Molecular Sciences·Andrea OrsiGiancarlo Icardi
Nov 19, 2017·Respirology : Official Journal of the Asian Pacific Society of Respirology·Jane Hadfield, Lesley Bennett
May 30, 2021·Vaccine·Courtney GidengilSusanne Hempel